Pentixapharm Holding AG (ETR:PTP) | WebDisclosure

Basculer en Français

10630	Companies
225961	Keywords
154508	Articles
119607	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

PRESS RELEASE

published on 10/06/2025 at 11:00, 8 months 18 days ago

Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Pentixapharm presents new clinical findings on expanding CXCR4 radiopharmaceutical platform at EANM 2025, demonstrating potential in diagnosis and therapeutics in Primary Aldosteronism and bladder cancer

Pentixapharm CXCR4 Radiopharmaceutical EANM 2025 Clinical Findings
BRIEF

published on 09/26/2025 at 08:05, 8 months 28 days ago

Pentixapharm Advances PentixaTher in AML Trial

Clinical Trial Radiopharmaceuticals Acute Myeloid Leukemia PentixaTher CXCR4-targeting
BRIEF

published on 09/26/2025 at 08:05, 8 months 28 days ago

Pentixapharm fait progresser PentixaTher dans l'essai sur la LAM

Essai Clinique Produits Radiopharmaceutiques Ciblage CXCR4 Leucémie Myéloïde Aiguë PentixaTher
PRESS RELEASE

published on 09/26/2025 at 08:00, 8 months 28 days ago

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial
Pentixapharm advances PentixaTher to fourth dose level in AML trial, reinforcing safety profile and potential clinical efficacy for CXCR4-targeted radiotherapeutic in high unmet need indication

Pentixapharm CXCR4 Acute Myeloid Leukemia Radiotherapeutic PentixaTher
BRIEF

published on 05/27/2025 at 09:48, 1 year ago

Pentixapharm Unveils New Clinical Development Strategy

Oncology Pentixapharm CXCR4 Trials Theranostic Strategy Hematologic Malignancies
BRIEF

published on 05/27/2025 at 09:48, 1 year ago

Pentixapharm dévoile une nouvelle stratégie de développement clinique

Oncologie Pentixapharm Essais CXCR4 Stratégie Théranostique Hémopathies Malignes
PRESS RELEASE

published on 05/27/2025 at 09:43, 1 year ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Pentixapharm outlines new clinical development strategy focusing on CXCR4 therapeutic and diagnostic oncology programs, discontinuing PTF301 trial in MZL, preparing new trials in hematologic malignancies and Bladder Cancer

Pentixapharm CXCR4 Oncology Programs Clinical Development Strategy Theranostic Precision
BRIEF

published on 04/25/2025 at 15:44, 1 year 1 month ago

Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025

Cancer Therapy Pentixapharm GT-008 Antibody Glycan-Dependent CD24 Targeting
BRIEF

published on 04/25/2025 at 15:44, 1 year 1 month ago

Pentixapharm présentera son anticorps innovant GT-008 à l'AACR 2025

Thérapie Contre Le Cancer Pentixapharm Anticorps GT-008 Glycane-dépendant Ciblage CD24
PRESS RELEASE

published on 04/25/2025 at 15:39, 1 year 1 month ago

Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
Pentixapharm to present novel CD24 antibody GT-008 for solid tumors at AACR 2025, showcasing glycan-dependent mechanism for targeted therapy

Solid Tumors Pentixapharm AACR 2025 GT-008 CD24 Antibody

Accesswire

Published on 06/25/2026 at 00:30, 3 hours 57 minutes ago

Northern Dynasty Reports Annual General Meeting Results and Welcomes New Directors
Published on 06/24/2026 at 23:05, 5 hours 22 minutes ago

Polaris Modifies Quorum Requirement for Upcoming AGM
Published on 06/24/2026 at 22:15, 6 hours 12 minutes ago

Organto Foods Announces Annual General Meeting Results
Published on 06/24/2026 at 21:20, 7 hours 7 minutes ago

Taranis to Explore New Properties East of Thor Mineral Resource
Published on 06/24/2026 at 20:10, 8 hours 17 minutes ago

Fox River Obtains Final Order Approving Plan of Arrangement With Avenir Minerals Limited

View all ACCESSWIRE

EQS Group

Published on 06/25/2026 at 03:20, 1 hour 7 minutes ago

ZTT at Intersolar Europe 2026: Full-Industry-Chain Strength Powering a Low-Carbon Future
Published on 06/24/2026 at 23:57, 4 hours 30 minutes ago

OHB: Upsized private placement worth EUR 900 million successfully completed
Published on 06/24/2026 at 20:54, 7 hours 32 minutes ago

EQS-Adhoc: Branicks Group AG sets out timetable for the publication of its 2025 annual and consolidated financial statements
Published on 06/24/2026 at 18:29, 9 hours 58 minutes ago

Designated Person Notification
Published on 06/24/2026 at 18:29, 9 hours 58 minutes ago

Designated Person Notification

Les Echos

Published on 06/24/2026 at 19:00, 9 hours 27 minutes ago

ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
Published on 06/24/2026 at 18:00, 10 hours 27 minutes ago

Annual Results 2025-26
Published on 06/24/2026 at 18:00, 10 hours 27 minutes ago

CP résultats annuels 2025-26
Published on 06/24/2026 at 18:00, 10 hours 27 minutes ago

KERLINK : Assemblée générale mixte des actionnaires du 23 juin 2026 Seconde convocation le 9 juillet 2026.
Published on 06/24/2026 at 17:45, 10 hours 42 minutes ago

Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno

View all LES ECHOS COMFI WIRE